Clinical Data Integrity: Clean US FDA Inspection No Guarantee That DoJ Won’t Investigate

Justice department has investigative tools that can uncover fraudulent activity even when a clinical site passes inspection, DoJ’s Clint Narver says; in deciding whether to self-report possible clinical trial fraud to FDA and DoJ, sponsors should consider that other companies would benefit from knowing this information about a particular site or investigator.  

Escalator
Drug sponsors need to have clear processes in place for escalating concerns about clinical data fraud. • Source: Shutterstock

A “glowing” US Food and Drug Administration inspection may not protect a pharmaceutical sponsor, contract research organization or site investigator from a Department of Justice investigation into potential clinical trial fraud.

Although DoJ looks at an entity’s inspectional history, that may not tell the full story in terms of whether fraud...

More from Clinical Trials

More from R&D